However, since only ~ 15% of ER+HER2− breast cancer patients would experience recurrence at 5 years in the absence of adjuvant chemotherapy [8], 85% of patients may be exposed to chemotherapy toxicity with minimal clinical benefit. This evidence concerns the gene ESR1 and breast cancer.